相关实验视频

Updated: Jun 20, 2025

A11-positive β-amyloid Oligomer Preparation and Assessment Using Dot Blotting Analysis

A11-positive β-amyloid Oligomer Preparation and Assessment Using Dot Blotting Analysis

Published on: May 22, 2018

赫里珊瑚酸多糖的结构性表征及其在阿尔茨海默病中的神经保护功能

Yue Guan¹, Chunyue Wang¹, Lanzhou Li¹

¹Engineering Research Center of Chinese Ministry of Education for Edible and Medicinal Fungi, School of Plant Protection, Jilin Agricultural University, Changchun 130118, China.

International journal of biological macromolecules

|July 17, 2024

概括

珊瑚酸聚糖 (Hericium coralloides polysaccharide,简称HCP) 在治疗阿尔茨海默氏症 (AD) 方面表现有前途. 这种天然化合物通过在小鼠模型中增强自性来减少认知衰退,粉样β斑块和神经炎症.

科学领域:

神经科学是一个神经科学.
生物化学生物化学
药理学药理学是指药理学的学科.

背景情况:

阿尔茨海默病 (AD) 是一种流行的神经退行性疾病.
多糖具有科学证明的神经保护性质.
珊瑚酸是一种具有潜在治疗应用的.

研究的目的:

从Hericium coralloides (HCP) 中分离和描述一个多糖类.
在阿尔茨海默病小鼠模型中研究HCP的神经保护作用.
阐明医疗人员治疗潜力的基础机制.

主要方法:

使用热水提取和柱状染色法,隔离和净化HCP.
在APP/PS1小鼠中使用降级和莫里斯水迷宫测试来评估认知功能.
通过免疫光学和西部涂抹分析粉样β斑块,化陶,神经炎症和微质极化.
蛋白质组分析以探索肠道微生物群和代谢物的作用.

主要成果:

在AD小鼠模型中,HCP,一个银河系 (16.06 kDa),改善了认知障碍.
用HCP治疗在8周内减少了粉样β斑块和酸化沉积.
通过增加自流量,降低神经炎症,HCP促进了M2微质的两极分化.

结论:

珊瑚酸聚糖 (HCP) 显示出对抗阿尔茨海默病的显著神经保护作用.
通过增强自流,HCP可以减轻神经炎症和认知缺陷.
HCP显示出作为阿尔茨海默病治疗的治疗剂的潜力.

关键词:

自自是一种自的过程.珊瑚合金是一种多糖化合物.神经保护是一种神经保护.

更多相关视频

Visualizing Axonal Growth Cone Collapse and Early Amyloid β Effects in Cultured Mouse Neurons

Visualizing Axonal Growth Cone Collapse and Early Amyloid β Effects in Cultured Mouse Neurons

Published on: October 30, 2018

Caenorhabditis elegans as a Model System for Discovering Bioactive Compounds Against Polyglutamine-Mediated Neurotoxicity

Caenorhabditis elegans as a Model System for Discovering Bioactive Compounds Against Polyglutamine-Mediated Neurotoxicity

Published on: September 21, 2021

相关概念视频

Alzheimer's Disease: Overview

Alzheimer's Disease: Overview

Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...

Alzheimer's Disease: Treatment

Alzheimer's Disease: Treatment

Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...